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Extramammary Paget's disease is a rare cutaneous malignant neoplasm. Previous studies 
indicated the efficacy of docetaxel in advanced cases. The common side effects of docetaxel 
are usually tolerable and seldom life-threatening. We experienced a case of severe 
pseudomembranous colitis and neutropenic fever that developed just after the first cycle of 
docetaxel chemotherapy. To the best of our knowledge, there are few reports of 
pseudomembranous colitis associated with docetaxel administration for skin cancers. The 
patient showed complete resolution of her symptoms within 2 weeks with an oral 
metronidazole therapy. During the second and third cycles, the patient received docetaxel 
safely with lower doses. The present case indicated that pseudomembranous colitis should 
be included in the differential diagnosis when assessing patients who develop severe 
diarrhea during systemic chemotherapy with docetaxel. 
 
Introduction 
Extramammary Paget’s disease (EMPD) is a rare cutaneous malignant neoplasm that 
arises in areas in the apocrine glands. Although EMPD is usually a non-invasive 
intraepithelial adenocarcinoma, some cases of EMPD infiltrate the dermis and show 
lymph node or distant metastases. Previous studies have shown cases of advanced 
EMPD successfully treated with docetaxel [1]. Common side effects of docetaxel are 
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usually tolerable and seldom life-threatening. We experienced a case of severe 
Clostridium difficile colitis and neutropenic fever that developed just after the first 
docetaxel chemotherapy for EMPD. To the best of our knowledge, there are few reports 
of C. difficile colitis associated with docetaxel use for skin cancer. 
Case Report 
A 67-year-old Japanese female with stage IV EMPD of the vulva was treated with 75 mg/m2 
docetaxel for the first time. Two weeks before docetaxel administration, oral cefcapene had been 
administered for 3 days at another clinic to prevent infection after biopsy of the vulva. On day 4 of the 
first cycle therapy, she developed severe watery diarrhea that quickly became bloody. On day 6, she 
was immediately admitted to the hospital. Physical and other examinations revealed grade 3 
neutropenic fever and diarrhea (Common Terminology Criteria for Adverse Events version 4.0) more 
than 10 times per day, with slight abdominal pain but no nausea or vomiting. She was treated with an 
injection of granulocyte colony-stimulating factor and piperacillin/tazobactam. Stool enzyme 
immunoassays for C. difficile toxins were positive. C. difficile colitis was diagnosed, and therefore an 
additional antibiotic therapy with oral metronidazole and antibiotic-resistant lactic acid bacteria drug 
was initiated. The patient had complete resolution of her symptoms within 2 weeks. One month after 
the administration of docetaxel, we found that the tumor had remarkably decreased in size and the 
serum tumor marker test showed a considerably decreased level of carcinoembryonic antigen (from 
158 ng/ml before to 13 ng/ml after chemotherapy). Therefore, we decided to pursue docetaxel 
treatment with a decreased dose of 37.5 mg/m2 after informed consent was obtained. During the 
second and third cycle, no apparent side effects other than neutropenia without fever were observed. 
The tumor continued to decrease in size, and the serum carcinoembryonic antigen level was 5 ng/ml 
after the third cycle of chemotherapy. 
Discussion 
C. difficile colitis is a well-known complication of antibiotic treatment that can also 
be observed, albeit rarely, with certain chemotherapeutic agents [2]. Some 
chemotherapeutic agents are also associated with different grades of inflammation and 
necrosis of the colonic mucosa with alteration of the intestinal flora [2]. This has been 
proposed as the pathophysiological mechanism responsible for the development of  
C. difficile colitis in some patients receiving these drugs [2]. Methotrexate has been the 
most commonly implicated agent of this class but platinum-containing drugs and 
taxanes are well-known for their potential to cause extensive inflammatory changes in 
the colonic mucosa, therefore creating a favorable environment for the overgrowth of  
C. difficile and production of its exotoxins [2]. Including the present case, there are 5 
cases of C. difficile colitis or pseudomembranous colitis related to docetaxel use (table 
1) [2, 3]. The patients developed colitis within 4 to 10 days after docetaxel 
administration, and 3 of the 5 patients developed neutropenia at the same time. The 
immunosuppressive condition due to neutropenia and inflammatory changes in the 
colonic mucosa caused by docetaxel might contribute to the development of severe  
C. difficile colitis. The cases indicated that C. difficile colitis should be included in the 
differential diagnosis when assessing patients who develop severe diarrhea during 
systemic chemotherapy with docetaxel. Including the present case, only 2 cases had 
positive stool assays for C. difficile toxin. Negative stool assays for C. difficile toxins 
should not lead the clinician away from this diagnosis if there is a strong suspicion of 
this disease. Colonoscopy or sigmoidoscopy are useful diagnostic procedures as the 
presence of pseudomembranes in the colon is pathognomonic of C. difficile-associated 
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disease. The present case also indicated the possibility that docetaxel treatment can be 
continued with lower doses even after the patient developed C. difficile colitis 
associated with docetaxel chemotherapy. 
Disclosure Statement 




Table 1. Review of the 5 cases of C. difficile colitis or pseudomembranous colitis associated with 
docetaxel use 
          
          
 Case 1  Case 2  Case 3  Case 4  Case 5  
(present case) 
          
          
Age/sex, years 83/male  47/male  41/female  45/female  67/female 
                    Diagnosis adenocarcinoma of 
the pancreas 
 adenocarcinoma of 
the lung 
 invasive ductal 
carcinoma of the breast 
 breast cancer  extramammary 
Paget's disease 
                    Chemotherapy 
(21-day cycles 
for all) 
day 1 and 8: 
docetaxel 30 mg/m2 
days 1–14:  
capecitabine 1,600 
mg/m2 
 day 1:  
docetaxel 70 mg/m2 
and carboplatin AUC 6 
 day 1:  
docetaxel 70 mg/m2 and 
cisplatin 70 mg/m2 
 day 1:  
docetaxel 75 mg/m2 
and doxorubicin 50 
mg/m2 
 day 1:  
docetaxel 75 mg/m2 





cycle 1 day 8 




pain on cycle 3  
day 10 
 severe diarrhea positive  
for occult blood,  
abdominal pain  
and leukocytosis on  
cycle 2 day 9 
severe watery 
diarrhea, vomitting, 
abdominal pain and 
neutropenic fever on 
cycle 1 day 6 and 
cycle 2 day 4 
 severe diarrhea 
positive for occult 
blood, abdominal 
pain and  
leukocytosis on  
cycle 1 day 4 
                    Antibiotic  
exposure 
no  no  no  unknown  cefcapene 1 week 
before 




 positive  
(2 of 3 samples) 
 negative  
(3 samples) 
 negative  positive  
(1 sample) 
                    Endoscopic 
findings 
pseudomembranes in 
the rectum, sigmoid 
and descending colon 
 pseudomembranes in 
the sigmoid and  
descending colon 
 moderate to severe  
mucosal inflammation  
of the sigmoid and the 
rectum with diffuse 
subepithelial 
hemorrhages 
 moderate inflamed 
rectal mucosa  
covered with 
pseudomembranes 
 not performed 
                    Treatment oral vancomycin  IV metronidazole and 
oral vancomycin 
 oral metronidazole  metronidazole and  
oral vancomycin 
 oral metronidazole 
                    Outcome symptoms resolved  symptoms resolved  symptoms resolved  symptoms resolved  symptoms resolved 
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